Faster global financial news!
Pharmaceutical Stocks
-
AI concept stocks fell, with funds flowing into large pharmaceutical stocks, and the State Street Healthcare ETF hit a new all-time high.
Funds are rapidly flowing into the large-cap pharmaceutical sector as AI concept stocks face a sell-off, according to Wallstreetcn.com. On Thursday, the State Street Health Care Select Sector SPDR ETF
-
Biohaven (BHVN) Stock Plummets After Pausing Midstage Seizure Treatment Study Due to Safety Concerns and FDA Toxicity Assessment Requirement
Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment opakalim due to safety concerns. The Food and Drug Administration (FDA) is now
-
Novartis' Late-Stage Trial for Rare Muscle Wasting Drug Fails, Marking Third Setback in a Week
Novartis' drug for a rare muscle-wasting disease failed in late-stage studies, marking the company's third clinical trial setback in a week. The drug, a core asset from Novartis' $12 billion acquisiti
-
Novartis's cholesterol drug Pelacarsen fails to significantly improve cardiovascular outcomes in Phase III trial; Amgen and Ionis shares decline.
Novartis announced after market close on Friday that its cholesterol drug Pelacarsen, co-developed with Ionis Pharmaceuticals, failed to significantly improve cardiovascular outcomes in late-stage cli
-
AI concept stocks fell, with funds flowing into large pharmaceutical stocks, and the State Street Healthcare ETF hit a new all-time high.
Funds are rapidly flowing into the large-cap pharmaceutical sector as AI concept stocks face a sell-off, according to Wallstreetcn.com. On Thursday, the State Street Health Care Select Sector SPDR ETF
-
Biohaven (BHVN) Stock Plummets After Pausing Midstage Seizure Treatment Study Due to Safety Concerns and FDA Toxicity Assessment Requirement
Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment opakalim due to safety concerns. The Food and Drug Administration (FDA) is now
-
Novartis' Late-Stage Trial for Rare Muscle Wasting Drug Fails, Marking Third Setback in a Week
Novartis' drug for a rare muscle-wasting disease failed in late-stage studies, marking the company's third clinical trial setback in a week. The drug, a core asset from Novartis' $12 billion acquisiti
-
Novartis's cholesterol drug Pelacarsen fails to significantly improve cardiovascular outcomes in Phase III trial; Amgen and Ionis shares decline.
Novartis announced after market close on Friday that its cholesterol drug Pelacarsen, co-developed with Ionis Pharmaceuticals, failed to significantly improve cardiovascular outcomes in late-stage cli
- No data
Pharmaceutical Stocks
24H Trending
-
1
IFO Concept Analysis: A New Paradigm for DeFi Fundraising and Its Representative Tokens
-
2
MASKDOGE Coin Analysis: Meme Token on BSC Chain and Trading Status
-
3
Nomura: AI growth panic replaces inflation narrative, U.S. Treasuries regain hedging function; Thursday's 10-year U.S. Treasury yield plunged over 15 basis points, Nasdaq Composite plummeted 2.6%.
-
4
METO Coin (Metafluence) Value Analysis and Investment Risk Assessment
-
5
Chainlink (LINK) Price Dynamics, Whale Accumulation, and Oracle Infrastructure Progress
-
6
Is Ethereum a Competitor to Bitcoin? An In-Depth Analysis of Their Relationship
-
7
How to Sell Bitcoin Cash (BCH) and Its Main Trading Markets
-
8
How to Track Bitcoin Whale Movements: On-Chain Data and Professional Tools Analysis
-
9
Distinguishing Between Memecoins with "GERMANY" in Their Name: Germany Coin (GER) and Germany Rabbit Token
-
10
OAX Token Analysis: The Native Token of the OpenANX Project and Its Trading Status
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
